Strategic Partnership IBEX recently announced a collaboration with Sus Clinicals to accelerate oncologic innovations in medical device testing, signaling openness to co-development opportunities and expanded capabilities that can be leveraged for joint go-to-market strategies.

Expanded Capabilities With over 20 years in preclinical testing across multiple therapeutic areas and non-surgical studies, IBEX offers a broad, end-to-end service portfolio that can be positioned to win larger, multi-study contracts from medtech innovators seeking comprehensive safety and performance data.

Quality & Compliance As an AAALAC accredited, GLP-compliant facility staffed by veterinary surgeons and research associates, IBEX presents a credible, high-standard option for sponsors requiring rigorous regulatory-ready preclinical data.

Growth Signals A mid-sized CRO in the preclinical space with revenue in the lower-to-mid single digits, IBEX is likely seeking strategic partnerships, client diversification, and scalable capacity to grow; this presents a doorway for scalable, long-term engagements.

Targeted Outreach Industry focus areas including orthopedics, wound care, ophthalmology, cardiovascular, GI, implant toxicity, and oncology-related models indicate several cross-sell paths; tailor outreach to medtech firms needing robust veterinary-driven preclinical programs with both surgical and non-surgical study options.